Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells.
Alerting Network Dysfunction in Early Multiple Sclerosis.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
[Experience of using genfaxon for treating patients with relapsing-remitting multiple sclerosis in the Russian Federation.]
Effect of Glatiramer Acetate on Peripheral Blood Brain-Derived Neurotrophic Factor and Phosphorylated TrkB Levels in Relapsing-Remitting Multiple Sclerosis.
Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis (TOPIC)
Mechanism-based CNS Disease Modeling: Applications in Neurology and Psychiatry Drug Research & Development
Effects of 2-Chlorodeoxyadenosine (Cladribine) on Primary Rat Microglia.
The potential teratogenic effects of interferon beta-1a (IFNβ-1a) and interferon beta-1b (IFNβ-1b) on in vitro embryonic development.
Complex antibody profiling to predict clinical outcome in childhood ADS.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Novel MS Drug Offers Good Functional Outcomes
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
Pericytes are required for blood-brain barrier integrity during embryogenesis.
Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Treatment of neurological injury with thymosin β4.
Efficacy and safety study of RPC1063 in relapsing multiple sclerosis patients
A newborn with Pierre Robin sequence after preconceptional mitoxantrone exposure of a female with multiple sclerosis.
Pages
« first
‹ previous
…
103
104
105
106
107
108
109
110
111
…
next ›
last »